Published in J Biol Chem on August 07, 1998
TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev (1999) 6.93
RANK is essential for osteoclast and lymph node development. Genes Dev (1999) 5.85
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A (1999) 5.78
Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of I kappa B kinase activation. J Biol Chem (2006) 3.51
The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology (2005) 3.18
Requirement of tumor necrosis factor receptor-associated factor (TRAF)6 in interleukin 17 signal transduction. J Exp Med (2000) 3.14
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol (1999) 2.78
Osteoimmunology: interactions of the bone and immune system. Endocr Rev (2008) 2.32
Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci U S A (2000) 2.20
Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J Cell Biol (2000) 2.04
TAK1-dependent signaling requires functional interaction with TAB2/TAB3. J Biol Chem (2006) 1.56
Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. Mol Cell Biol (2002) 1.53
Role of NF-κB in the skeleton. Cell Res (2010) 1.45
Concern Modification of the cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by xanthohumol leads to suppression of NF-kappaB-regulated gene products and potentiation of apoptosis in leukemia cells. Blood (2008) 1.42
Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells. BMC Complement Altern Med (2017) 1.39
Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis (2002) 1.35
Targeting subchondral bone for treating osteoarthritis: what is the evidence? Best Pract Res Clin Rheumatol (2010) 1.33
RelB/p52 NF-kappaB complexes rescue an early delay in mammary gland development in transgenic mice with targeted superrepressor IkappaB-alpha expression and promote carcinogenesis of the mammary gland. Mol Cell Biol (2005) 1.32
IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. J Clin Invest (2001) 1.31
TRAF6 ubiquitin ligase is essential for RANKL signaling and osteoclast differentiation. Biochem Biophys Res Commun (2007) 1.30
Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond. Front Immunol (2014) 1.29
The RING domain and first zinc finger of TRAF6 coordinate signaling by interleukin-1, lipopolysaccharide, and RANKL. J Biol Chem (2008) 1.23
Roles of tumor necrosis factor receptor associated factor 3 (TRAF3) and TRAF5 in immune cell functions. Immunol Rev (2011) 1.18
Mechanisms balancing skeletal matrix synthesis and degradation. Biochem J (2002) 1.12
Trolox prevents osteoclastogenesis by suppressing RANKL expression and signaling. J Biol Chem (2009) 1.11
RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro. PLoS One (2013) 1.08
Central role of TRAF-interacting protein in a new model of brain sexual differentiation. Proc Natl Acad Sci U S A (2009) 1.07
Molecular profiles and clinical outcome of stage UICC II colon cancer patients. Int J Colorectal Dis (2011) 1.05
Jun dimerization protein 2 (JDP2), a member of the AP-1 family of transcription factor, mediates osteoclast differentiation induced by RANKL. J Exp Med (2003) 1.04
Differential modulation of RANKL isoforms by human osteoarthritic subchondral bone osteoblasts: influence of osteotropic factors. Bone (2008) 1.02
The Keap1/Nrf2 protein axis plays a role in osteoclast differentiation by regulating intracellular reactive oxygen species signaling. J Biol Chem (2013) 1.00
Endogenous n-3 fatty acids protect ovariectomy induced bone loss by attenuating osteoclastogenesis. J Cell Mol Med (2009) 0.99
Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling. Mol Cancer Ther (2011) 0.97
Osteoclasts: New Insights. Bone Res (2013) 0.97
NF-kappaB signal triggering and termination by tumor necrosis factor receptor 2. J Biol Chem (2011) 0.97
Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors. Ann Rheum Dis (1999) 0.96
Signaling Pathways in Osteoclast Differentiation. Chonnam Med J (2016) 0.94
Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis. Expert Opin Ther Targets (2010) 0.92
C-Src-mediated RANKL-induced breast cancer cell migration by activation of the ERK and Akt pathway. Oncol Lett (2011) 0.92
Escin, a pentacyclic triterpene, chemosensitizes human tumor cells through inhibition of nuclear factor-kappaB signaling pathway. Mol Pharmacol (2010) 0.91
Meningioma 1 is required for appropriate osteoblast proliferation, motility, differentiation, and function. J Biol Chem (2009) 0.90
Role of the A20-TRAF6 axis in lipopolysaccharide-mediated osteoclastogenesis. J Biol Chem (2010) 0.90
Diacerein inhibits the synthesis of resorptive enzymes and reduces osteoclastic differentiation/survival in osteoarthritic subchondral bone: a possible mechanism for a protective effect against subchondral bone remodelling. Arthritis Res Ther (2008) 0.90
RANKL up-regulates brain-type creatine kinase via poly(ADP-ribose) polymerase-1 during osteoclastogenesis. J Biol Chem (2010) 0.87
Pubertal high fat diet: effects on mammary cancer development. Breast Cancer Res (2013) 0.87
Role of RANKL-RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications. Indian J Endocrinol Metab (2011) 0.87
The adaptor protein p62/SQSTM1 in osteoclast signaling pathways. J Mol Signal (2012) 0.86
Deletion of CD74, a putative MIF receptor, in mice enhances osteoclastogenesis and decreases bone mass. J Bone Miner Res (2013) 0.85
RANKL-RANK interaction in immune regulatory systems. World J Orthop (2012) 0.85
Identification of novel human receptor activator of nuclear factor-kB isoforms generated through alternative splicing: implications in breast cancer cell survival and migration. Breast Cancer Res (2012) 0.83
Inhibitory effect of luteolin on osteoclast differentiation and function. Cytotechnology (2010) 0.83
Inhibition of osteoclast differentiation and bone resorption by N-methylpyrrolidone. J Biol Chem (2011) 0.83
2-Methoxystypandrone represses RANKL-mediated osteoclastogenesis by down-regulating formation of TRAF6-TAK1 signalling complexes. Br J Pharmacol (2010) 0.83
TNFRSF11A and TNFSF11 are associated with age at menarche and natural menopause in white women. Menopause (2010) 0.83
RANK (TNFRSF11A) is epigenetically inactivated and induces apoptosis in gliomas. Neoplasia (2012) 0.83
Palmitic acid and DGAT1 deficiency enhance osteoclastogenesis, while oleic acid-induced triglyceride formation prevents it. J Bone Miner Res (2014) 0.83
The role of TNF-α and TNF superfamily members in the pathogenesis of calcific aortic valvular disease. ScientificWorldJournal (2013) 0.82
Water solution of onion crude powder inhibits RANKL-induced osteoclastogenesis through ERK, p38 and NF-kappaB pathways. Osteoporos Int (2008) 0.81
Epidermal growth factor receptor (EGFR) signaling is a key mediator of hormone-induced leukocyte infiltration in the pubertal female mammary gland. Endocrinology (2014) 0.81
(+)-Vitisin A inhibits osteoclast differentiation by preventing TRAF6 ubiquitination and TRAF6-TAK1 formation to suppress NFATc1 activation. PLoS One (2014) 0.80
RNA therapeutics targeting osteoclast-mediated excessive bone resorption. Adv Drug Deliv Rev (2011) 0.80
Development of cell-based high-throughput assays for the identification of inhibitors of receptor activator of nuclear factor-kappa B signaling. Assay Drug Dev Technol (2010) 0.80
Clinical prognostic significance and pro-metastatic activity of RANK/RANKL via the AKT pathway in endometrial cancer. Oncotarget (2016) 0.80
RANKL signaling and osteoclastogenesis is negatively regulated by cardamonin. PLoS One (2013) 0.78
The alliance of mesenchymal stem cells, bone, and diabetes. Int J Endocrinol (2014) 0.78
A benzamide-linked small molecule NDMC101 inhibits NFATc1 and NF-κB activity: a potential osteoclastogenesis inhibitor for experimental arthritis. J Clin Immunol (2012) 0.78
A TRAF2 binding independent region of TNFR2 is responsible for TRAF2 depletion and enhancement of cytotoxicity driven by TNFR1. Oncotarget (2014) 0.78
Protective protein/cathepsin A down-regulates osteoclastogenesis by associating with and degrading NF-kappaB p50/p65. J Bone Miner Metab (2008) 0.78
The dectin 1 agonist curdlan regulates osteoclastogenesis by inhibiting nuclear factor of activated T cells cytoplasmic 1 (NFATc1) through Syk kinase. J Biol Chem (2014) 0.77
Inhibition of osteoclastogenesis by RNA interference targeting RANK. BMC Musculoskelet Disord (2012) 0.77
Negative autoregulation of RANKL and c-Src signaling in osteoclasts. J Bone Miner Metab (2007) 0.77
Association analyses suggest the effects of RANK and RANKL on age at menarche in Chinese women. Climacteric (2011) 0.77
Identification of novel RANK polymorphisms and their putative association with low BMD among postmenopausal women. Osteoporos Int (2006) 0.77
Molecular regulatory mechanisms of osteoclastogenesis through cytoprotective enzymes. Redox Biol (2016) 0.76
Desferrioxamine reduces ultrahigh-molecular-weight polyethylene-induced osteolysis by restraining inflammatory osteoclastogenesis via heme oxygenase-1. Cell Death Dis (2016) 0.75
WITHDRAWN: Cardamonin Inhibits Osteoclastogenesis Induced by Tumor Cells Through Interruption of the Signaling Pathway Activated by Receptor Activator of NF-κB Ligand. Cancer Lett (2011) 0.75
RANK receptor oligomerisation in the regulation of NFκB signalling. J Mol Endocrinol (2014) 0.75
Receptor activator of NF-kappaB ligand induces the fusion of mononuclear preosteoclasts into multinucleated osteoclasts. Cytotechnology (2000) 0.75
Induced Sézary syndrome PBMCs poorly express immune response genes up-regulated in stimulated memory T cells. J Dermatol Sci (2010) 0.75
Effects of electromagnetic radiation exposure on bone mineral density, thyroid, and oxidative stress index in electrical workers. Onco Targets Ther (2016) 0.75
Physiological role of receptor activator nuclear factor-kB (RANK) in denervation-induced muscle atrophy and dysfunction. Receptors Clin Investig (2016) 0.75
Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature (1985) 13.04
FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex. Cell (1996) 12.07
Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science (1985) 7.99
LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol (1999) 7.27
Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors. J Immunol (1985) 7.20
The receptor for the cytotoxic ligand TRAIL. Science (1997) 6.39
IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science (1997) 6.30
Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem (1985) 6.28
An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science (1997) 6.10
Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity. Nature (1985) 5.41
Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon. Nature (1986) 4.98
Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. Proc Natl Acad Sci U S A (1996) 4.11
B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol (2001) 4.10
Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem (1995) 4.05
Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-kappaB. J Biol Chem (1999) 3.81
Identification of a member of the interferon regulatory factor family that binds to the interferon-stimulated response element and activates expression of interferon-induced genes. Proc Natl Acad Sci U S A (1995) 3.62
Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood (2001) 3.39
Regulation of type I interferon gene expression by interferon regulatory factor-3. J Biol Chem (1998) 3.31
Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes. J Biol Chem (2001) 3.26
Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science (1996) 2.87
Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol (2000) 2.86
Life-threatening reactions after pedodontic sedation: an assessment of narcotic, local anesthetic, and antiemetic drug interaction. J Am Dent Assoc (1983) 2.64
RIP2 is a novel NF-kappaB-activating and cell death-inducing kinase. J Biol Chem (1998) 2.58
NF-κB addiction and its role in cancer: 'one size does not fit all'. Oncogene (2010) 2.56
Human lymphotoxin. Production by a lymphoblastoid cell line, purification, and initial characterization. J Biol Chem (1984) 2.55
Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. J Biol Chem (1999) 2.44
Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase. J Biol Chem (1999) 2.41
Tumor necrosis factors: gene structure and biological activities. Cold Spring Harb Symp Quant Biol (1986) 2.38
Interrelationships of human interferon-gamma with lymphotoxin and monocyte cytotoxin. J Exp Med (1984) 2.33
Human interleukin 1 is a cytocidal factor for several tumor cell lines. J Immunol (1985) 2.31
Identification of human proteins functionally conserved with the yeast putative adaptors ADA2 and GCN5. Mol Cell Biol (1996) 2.30
Antisense snoRNAs: a family of nucleolar RNAs with long complementarities to rRNA. Trends Biochem Sci (1995) 2.29
LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol (2000) 2.27
Overexpression of manganese superoxide dismutase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-kappaB and activated protein-1. J Biol Chem (1998) 2.26
Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia (2002) 2.26
Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat Med (2000) 2.18
Characterization of the interferon regulatory factor-7 and its potential role in the transcription activation of interferon A genes. J Biol Chem (1998) 2.08
Natural killer-sensitive targets stimulate production of TNF-alpha but not TNF-beta (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes. J Immunol (1986) 2.05
A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J Biol Chem (1997) 2.00
A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem (1999) 1.98
Identification of human uromodulin as the Tamm-Horsfall urinary glycoprotein. Science (1987) 1.92
Interferons and tumor necrosis factors have similar catabolic effects on 3T3 L1 cells. Proc Natl Acad Sci U S A (1986) 1.91
LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest (1998) 1.89
I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis. J Biol Chem (1997) 1.86
Risk appraisal of narcotic sedation for children. Anesth Prog (1986) 1.82
The synergistic anti-proliferative effect of gamma-interferon and human lymphotoxin. J Immunol (1984) 1.81
Receptor binding and activation of polymorphonuclear neutrophils by tumor necrosis factor-alpha. J Leukoc Biol (1987) 1.81
Molecular cloning of the small (gamma) subunit of human TFIIA reveals functions critical for activated transcription. Genes Dev (1994) 1.80
Association of viral genome with graft loss in children after cardiac transplantation. N Engl J Med (2001) 1.78
Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS. Blood (2000) 1.76
CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer (2008) 1.75
Identification and functional characterization of DR6, a novel death domain-containing TNF receptor. FEBS Lett (1998) 1.75
Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J Biol Chem (2000) 1.72
Detection of microorganisms in the tracheal aspirates of preterm infants by polymerase chain reaction: association of adenovirus infection with bronchopulmonary dysplasia. Pediatr Res (2000) 1.72
TNF-induced signaling in apoptosis. J Clin Immunol (1999) 1.71
Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-kappaB activation and proliferation in human head and neck squamous cell carcinoma. Oncogene (2006) 1.68
Antitumor activity of the novel human breast cancer growth inhibitor, mammary-derived growth inhibitor-related gene, MRG. Cancer Res (1997) 1.66
Assay for redox-sensitive transcription factor. Methods Enzymol (2000) 1.65
Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood (2001) 1.64
Primary structure of human lymphotoxin derived from 1788 lymphoblastoid cell line. J Biol Chem (1985) 1.64
Siglec-8. A novel eosinophil-specific member of the immunoglobulin superfamily. J Biol Chem (2000) 1.59
Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene (2001) 1.58
Acute myocarditis. Rapid diagnosis by PCR in children. Circulation (1994) 1.58
Over-the-counter analgesics and antipyretics: a critical assessment. Clin Ther (2000) 1.58
The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol (2001) 1.54
TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEBS Lett (1998) 1.54
Inhibition of mammalian legumain by some cystatins is due to a novel second reactive site. J Biol Chem (1999) 1.52
Seismic images of crust and upper mantle beneath Tibet: evidence for Eurasian plate subduction. Science (2002) 1.52
Alpha-melanocyte-stimulating hormone inhibits the nuclear transcription factor NF-kappa B activation induced by various inflammatory agents. J Immunol (1998) 1.51
Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis (2013) 1.51
Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity. J Immunol (1987) 1.49
Cloning of Drosophila GCN5: conserved features among metazoan GCN5 family members. Nucleic Acids Res (1998) 1.47
Environmental impacts and sustainability of egg production systems. Poult Sci (2011) 1.46
Interferon-kappa, a novel type I interferon expressed in human keratinocytes. J Biol Chem (2001) 1.45
Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes. J Biol Chem (1999) 1.44
Extracellular matrix protein 1 (ECM1) has angiogenic properties and is expressed by breast tumor cells. FASEB J (2001) 1.42
Lobster sniffing: antennule design and hydrodynamic filtering of information in an odor plume. Science (2001) 1.41
Identification of a novel activation-inducible protein of the tumor necrosis factor receptor superfamily and its ligand. J Biol Chem (1999) 1.41
TNF induces internalization of the p60 receptor and shedding of the p80 receptor. J Immunol (1994) 1.41
Inhibition of tumor necrosis factor (TNF-alpha)-mediated apoptosis by hepatitis C virus core protein. J Biol Chem (1998) 1.40
Characterization of the in vitro and in vivo species preference of human and murine tumor necrosis factor-alpha. Cancer Res (1988) 1.39
The utilisation of research in practice. Prof Nurse (1995) 1.39
Human tumor necrosis factor-alpha receptor. Purification by immunoaffinity chromatography and initial characterization. J Biol Chem (1988) 1.38
The human extracellular matrix gene 1 (ECM1): genomic structure, cDNA cloning, expression pattern, and chromosomal localization. Genomics (1997) 1.38
Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol (2000) 1.37
Epidermal growth factor (EGF) activates nuclear factor-kappaB through IkappaBalpha kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of IkappaBalpha. Oncogene (2007) 1.36
Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. J Biol Chem (1998) 1.36
Expansion of CD133(+) colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery. Br J Cancer (2010) 1.35
Identification and characterization of human endometase (Matrix metalloproteinase-26) from endometrial tumor. J Biol Chem (2000) 1.35
Insulin-dependent diabetes mellitus and oral soft tissue pathologies. I. Prevalence and characteristics of non-candidal lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2000) 1.35
Insulin-dependent diabetes mellitus and oral soft tissue pathologies: II. Prevalence and characteristics of Candida and Candidal lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2000) 1.34
Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol (1999) 1.33
Oleandrin suppresses activation of nuclear transcription factor-kappaB, activator protein-1, and c-Jun NH2-terminal kinase. Cancer Res (2000) 1.33
Genetic deletion of PKR abrogates TNF-induced activation of IkappaBalpha kinase, JNK, Akt and cell proliferation but potentiates p44/p42 MAPK and p38 MAPK activation. Oncogene (2006) 1.33